Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07200206) titled 'A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea' on Sept. 29.
Study Type: Observational
Primary Sponsor: Sanofi
Condition:
Respiratory Syncytial Virus
Intervention:
Biological: Nirsevimab
Recruitment Status: Not recruiting
Date of First Enrollment: October 1, 2025
Target Sample Size: 3000
To know more, visit https://clinicaltrials.gov/study/NCT07200206
Published by HT Digital Content Services with permission from Health Daily Digest....